ROSIGLITAZONE AND FENOFIBRATE IMPROVE HDL METABOLISM ASSESSED BY FERHDL

Autor:	Michal Vrablík, L. Zlatohlavek, M. Dobiasova, Richard Ceska, Tomáš Štulc, R. Dolezalova, Z. Kasalova
Rok vydání:	2008
Předmět:	medicine.medical_specialty Fenofibrate Endocrinology business.industry Internal medicine Internal Medicine Medicine General Medicine Hdl metabolism Cardiology and Cardiovascular Medicine business Rosiglitazone medicine.drug
Zdroj:	Atherosclerosis Supplements. 9:191-192
ISSN:	1567-5688
DOI:	10.1016/s1567-5688(08)70767-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9311eecb7918dbbec8da8489668142fa https://doi.org/10.1016/s1567-5688(08)70767-0 Zobrazit plný text záznamu Full Text from ScienceDirect